Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

N/A

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 3(3)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03649503Recruiting

The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

Role: collaborator

NCT06254690Phase 2Recruiting

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Role: collaborator

NCT06246461Not ApplicableCompleted

The Therapeutic Effect of Different Doses of Capecitabine

Role: lead

NCT05606549Not ApplicableUnknown

Effect of MSD on FCR Among Gastric Cancer Survivors

Role: collaborator

NCT05166733Unknown

A Retrospective Study of Reco Thrombectomy Stent for Intravascular Treatment of Acute Ischemic Stroke

Role: collaborator

NCT04287660Phase 3Unknown

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Role: collaborator

NCT04087967Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Role: collaborator

NCT04083911Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Role: collaborator

All 8 trials loaded